Disease modifying therapies in multiple sclerosis: Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines
Top Cited Papers
Open Access
- 22 January 2002
- journal article
- guideline
- Published by Ovid Technologies (Wolters Kluwer Health) in Neurology
- Vol. 58 (2), 169-178
- https://doi.org/10.1212/wnl.58.2.169
Abstract
No abstract availableThis publication has 46 references indexed in Scilit:
- United States open-label glatiramer acetate extension trial for relapsing multiple sclerosis: MRI and clinical correlatesMultiple Sclerosis Journal, 2001
- Pharmacodynamic Comparison of Single Doses of IFN-beta 1a and IFN-beta 1b in Healthy VolunteersJournal of Interferon & Cytokine Research, 1999
- Axonal damage in acute multiple sclerosis lesionsBrain, 1997
- Pharmacokinetics and Pharmacodynamics of Recombinant Human Interferon-β in Healthy Male VolunteersJournal of Interferon & Cytokine Research, 1996
- EPIDEMIOLOGY OF MULTIPLE SCLEROSISNeurologic Clinics, 1996
- Defining the clinical course of multiple sclerosisNeurology, 1996
- Copolymer 1 reduces relapse rate and improves disability in relapsing‐remitting multiple sclerosisNeurology, 1995
- Applications of global statistics in analysing quality of life dataStatistics in Medicine, 1990
- More powerful procedures for multiple significance testingStatistics in Medicine, 1990
- A Pilot Trial of Cop 1 in Exacerbating–Remitting Multiple SclerosisThe New England Journal of Medicine, 1987